The short version of purity assay fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
| Property | Value | Notes |
|---|---|---|
| Common separation technique | Reversed-phase HPLC | Separates mainly by hydrophobicity; gradient elution is typical. |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; also detects many organic impurities. |
| Identity confirmation method | LC-MS or MALDI-MS | Provides molecular mass; not a stand-alone quantitative purity measure. |
| Aggregate assessment method | Size-exclusion chromatography | Detects dimers, oligomers, and larger species. |
| Content assessment method | Amino acid analysis | Estimates peptide mass fraction after hydrolysis and separation. |
Peptide purity can change during storage, handling, and reconstitution, and lyophilized peptides are generally more stable than solutions because water promotes hydrolysis and aggregation. Residual moisture, oxygen, and trace metals can accelerate degradation even in solid form. Temperature fluctuations during shipping may cause condensation and local moisture uptake. Quality control therefore includes appearance, water content, and analytical testing before and after storage challenges. Peptides containing cysteine, methionine, or tryptophan are especially susceptible to oxidation, while asparagine and glutamine residues can deamidate under neutral or alkaline conditions.
Analytical quality control compares a stored sample against a baseline profile. Reverse-phase chromatography remains common, but stability studies may also use mass spectrometry to detect oxidation, deamidation, or truncation products. Accelerated aging at elevated temperature can reveal degradation pathways, although extrapolation to room temperature is uncertain. Forced degradation studies expose peptides to heat, light, acid, base, and oxidants to identify likely breakdown products. Documentation should record lot number, storage history, and the exact method used for each measurement.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Impurity profiles can include deletion peptides, oxidized forms, truncated sequences, and residual solvents. Some impurities arise during synthesis, cleavage, or purification, while others form during storage. Purity testing often focuses on peptide-related impurities, whereas residual solvents and counterions require separate assays. The significance of a given impurity depends on its amount and properties, which may not be established for a research peptide. Reporting an impurity profile is more informative than reporting a single purity number.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
Peptide purity testing measures how much of a sample consists of the intended peptide sequence compared with related substances, water, counterions, and residual solvents. No single analytical method captures all of these components at once. Reversed-phase high-performance liquid chromatography with ultraviolet detection is widely used because it separates peptides by hydrophobicity. The reported purity value therefore depends on the chosen method, column, mobile phase, and detection wavelength. Established practice treats purity as method-dependent rather than an absolute property of the material.
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
=== Electricity demand and grid capacity === The proliferation of AI has driven a surge in data centre construction and power requirements. According to the National Energy System Operator (NESO), UK data centres consumed 5.0 TWh of electricity in 2023, equivalent to 2% of total UK electricity demand and 7% of commercial sector consumption. However, Oxford Economics forecasts that total demand could grow more than fivefold by 2030, reaching 26.2 TWh, which would represent 8.8% of total UK electricity demand and 30.4% of commercial electricity consumption. This rapid growth has created friction with the UK's net zero targets. In February 2026, the Environmental Audit Committee raised concerns that the government had not adequately factored data centre energy consumption into the draft Seventh Carbon Budget. The energy regulator Ofgem disclosed that developers of new data centres had enquired about grid connections that would require more energy at peak times than the whole of Britain consumes on some days.
Clinical psychology is an integration of human science, behavioral science, theory, and clinical knowledge aimed at understanding, preventing, and relieving psychological distress or dysfunction as well as promoting well-being and personal growth. Central to its practice are psychological assessment, diagnosis, clinical formulation, and psychotherapy; although clinical psychologists also engage in research, teaching, consultation, forensic testimony, and program development and administration. In many countries, clinical psychology is a regulated mental health profession. In the United States, clinical psychologists operate under the same license as counseling psychologists and school psychologists. The field is generally considered to have begun in 1896 with the opening of the first psychological clinic at the University of Pennsylvania by Lightner Witmer. In the first half of the 20th century, clinical psychology was focused on psychological assessment, with little attention given to treatment. This changed after the 1940s when World War II resulted in the need for a large increase in the number of trained clinicians. Since that time, three main educational models have developed in the US—the PhD Clinical Science model (heavily focused on research), the PhD science-practitioner model (integrating scientific research and practice), and the PsyD practitioner-scholar model (focusing on clinical theory and practice).
=== Mechanism === The cell membranes of bacteria are rich in acidic phospholipids, such as phosphatidylglycerol and cardiolipin. In contrast, the outer part of the membranes of plants and mammals is mainly composed of lipids without any net charges since most of the lipids with negatively charged headgroups are principally sequestered into the inner leaflet of the plasma membranes. Thus in the case of mammalian cells, the outer surfaces of the membranes are usually made of zwitterionic phosphatidylcholine and sphingomyelin, even though a small portion of the membrane's outer surfaces contain some negatively charged gangliosides. Therefore, the hydrophobic interaction between the hydrophobic face of amphipathic antimicrobial peptides and the zwitterionic phospholipids on the cell surface of mammalian cell membranes plays a major role in the formation of peptide-cell binding. Dual polarisation interferometry has been used in vitro to study and quantify the association to headgroup, insertion into the bilayer, pore formation and eventual disruption of the membrane.
=== Legal status === Oxycodone is subject to international conventions on narcotic drugs. In addition, oxycodone is subject to national laws that differ by country. The 1931 Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs of the League of Nations included oxycodone. The 1961 Single Convention on Narcotic Drugs of the United Nations, which replaced the 1931 convention, categorized oxycodone in Schedule I. Global restrictions on Schedule I drugs include "limit[ing] exclusively to medical and scientific purposes the production, manufacture, export, import, distribution of, trade in, use and possession of" these drugs; "requir[ing] medical prescriptions for the supply or dispensation of [these] drugs to individuals"; and "prevent[ing] the accumulation" of quantities of these drugs "in excess of those required for the normal conduct of business".
Sources: en.wikipedia.org
high-affinity glutamate and neutral amino acid transporter (SLC1A1, SLC1A2, SLC1A3, SLC1A4, SLC1A5, SLC1A6, SLC1A7) facilitative GLUT transporter (SLC2A1, SLC2A2, SLC2A3, SLC2A4, SLC2A5, SLC2A6, SLC2A7, SLC2A8, SLC2A9, SLC2A10, SLC2A11, SLC2A12, SLC2A13, SLC2A14) heavy subunits of heterodimeric amino acid transporters (SLC3A1, SLC3A2) bicarbonate transporter (SLC4A1, SLC4A2, SLC4A3, SLC4A4, SLC4A5, SLC4A6, SLC4A7, SLC4A8, SLC4A9, SLC4A10, SLC4A11) sodium glucose cotransporter (SLC5A1, SLC5A2, SLC5A3, SLC5A4, SLC5A5, SLC5A6, SLC5A7, SLC5A8, SLC5A9, SLC5A10, SLC5A11, SLC5A12) sodium- and chloride-dependent sodium:neurotransmitter symporters (SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A6, SLC6A7, SLC6A8, SLC6A9, SLC6A10, SLC6A11, SLC6A12, SLC6A13, SLC6A14, SLC6A15, SLC6A16, SLC6A17, SLC6A18, SLC6A19, SLC6A20) cationic amino acid transporter/glycoprotein-associated cationic amino acid transporters (SLC7A1, SLC7A2, SLC7A3, SLC7A4) glycoprotein-associated/light or catalytic subunits of heterodimeric amino acid transporters (SLC7A5, SLC7A6, SLC7A7, SLC7A8, SLC7A9, SLC7A10, SLC7A11, SLC7A13, SLC7A14) Na+/Ca2+ exchanger (SLC8A1, SLC8A2, SLC8A3) Na+/H+ exchanger (SLC9A1, SLC9A2, SLC9A3, SLC9A4, SLC9A5, SLC9A6, SLC9A7, SLC9A8, SLC9A9, SLC9A10, SLC9A11, SLC9B1, SLC9B2) sodium bile salt cotransport (SLC10A1, SLC10A2, SLC10A3, SLC10A4, SLC10A5, SLC10A6, SLC10A7) proton coupled metal ion transporter (SLC11A1, SLC11A2) electroneutral cation-Cl cotransporter (SLC12A1, SLC12A2, SLC12A3, SLC12A4, SLC12A5, SLC12A6, SLC12A7, SLC12A8, SLC12A9) Na+-sulfate/carboxylate cotransporter (SLC13A1, SLC13A2, SLC13A3, SLC13A4, SLC13A5) urea transporter (SLC14A1, SLC14A2) proton oligopeptide cotransporter (SLC15A1, SLC15A2, SLC15A3, SLC15A4) monocarboxylate transporter (SLC16A1, SLC16A2, SLC16A3, SLC16A4, SLC16A5, SLC16A6, SLC16A7, SLC16A8, SLC16A9, SLC16A10, SLC16A11, SLC16A12, SLC16A13, SLC16A14) vesicular glutamate transporter (SLC17A1, SLC17A2, SLC17A3, SLC17A4, SLC17A5, SLC17A6, SLC17A7, SLC17A8, SLC17A9) vesicular amine transporter (SLC18A1, SLC18A2, SLC18A3) folate/thiamine transporter (SLC19A1, SLC19A2, SLC19A3) type III Na+-phosphate cotransporter (SLC20A1, SLC20A2) organic anion transporting subfamily 1 (SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1) subfamily 2 (SLCO2A1, SLCO2B1) subfamily 3 (SLCO3A1) subfamily 4 (SLCO4A1, SLCO4C1) subfamily 5 (SLCO5A1) subfamily 6 (SLCO6A1) organic cation/anion/zwitterion transporter (SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5, SLC22A6, SLC22A7, SLC22A8, SLC22A9, SLC22A10, SLC22A11, SLC22A12, SLC22A13, SLC22A14, SLC22A15, SLC22A16, SLC22A17, SLC22A18, SLC22A18AS, SLC22A19, SLC22A20, SLC22A23, SLC22A24, SLC22A25, SLC22A31) Na+-dependent ascorbic acid transporter (SLC23A1, SLC23A2, SLC23A3, SLC23A4) Na+/(Ca2+-K+) exchanger (SLC24A1, SLC24A2, SLC24A3, SLC24A4, SLC24A5, SLC24A6) mitochondrial carrier (SLC25A1, SLC25A2, SLC25A3, SLC25A4, SLC25A5, SLC25A6, UCP1(SLC25A7), UCP2(SLC25A8), UCP3(SLC25A9), SLC25A10, SLC25A11, SLC25A12, SLC25A13, SLC25A14, SLC25A15, SLC25A16, SLC25A17, SLC25A18, SLC25A19, SLC25A20, SLC25A21, SLC25A22, SLC25A23, SLC25A24, SLC25A25, SLC25A26, SLC25A27, SLC25A28, SLC25A29, SLC25A30, SLC25A31, SLC25A32, SLC25A33, SLC25A34, SLC25A35, SLC25A36, SLC25A37, SLC25A38, SLC25A39, SLC25A40, SLC25A41, SLC25A42, SLC25A43, SLC25A44, SLC25A45, SLC25A46), SLC25A47, SLC25A48, MTCH1(SLC25A49), MTCH2(SLC25A50), SLC25A51, SLC25A52, SLC25A53 multifunctional anion exchanger (SLC26A1, SLC26A2, SLC26A3, SLC26A4, SLC26A5, SLC26A6, SLC26A7, SLC26A8, SLC26A9, SLC26A10, SLC26A11) fatty acid transport proteins (SLC27A1, SLC27A2, SLC27A3, SLC27A4, SLC27A5, SLC27A6) Na+-coupled nucleoside transport (SLC28A1, SLC28A2, SLC28A3) facilitative nucleoside transporter (SLC29A1, SLC29A2, SLC29A3, SLC29A4) zinc transporter (SLC30A1, SLC30A2, SLC30A3, SLC30A4, SLC30A5, SLC30A6, SLC30A7, SLC30A8, SLC30A9, SLC30A10) copper transporter (SLC31A1, SLC31A2) vesicular inhibitory amino acid transporter (SLC32A1) Acetyl-CoA transporter (SLC33A1) type II Na+-phosphate cotransporter (SLC34A1, SLC34A2, SLC34A3) nucleotide-sugar transporter subfamily A (SLC35A1, SLC35A2, SLC35A3, SLC35A4, SLC35A5) subfamily B (SLC35B1, SLC35B2, SLC35B3, SLC35B4) subfamily C (SLC35C1, SLC35C2) subfamily D (SLC35D1, SLC35D2, SLC35D3) subfamily E (SLC35E1, SLC35E2A, SLC35E2B, SLC35E3, SLC35E4) subfamily F (SLC35F1, SLC35F2, SLC35F3, SLC35F4, SLC35F5) subfamily G (SLC35G1, SLC35G3, SLC35G4, SLC35G5, SLC35G6) proton-coupled amino acid transporter (SLC36A1, SLC36A2, SLC36A3, SLC36A4) sugar-phosphate/phosphate exchanger (SLC37A1, SLC37A2, SLC37A3, SLC37A4) System A & N, sodium-coupled neutral amino acid transporter (SLC38A1, SLC38A2, SLC38A3, SLC38A4, SLC38A5, SLC38A6, SLC38A7, SLC38A8, SLC38A9, SLC38A10, SLC38A11) metal ion transporter (SLC39A1, SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A8, SLC39A9, SLC39A10, SLC39A11, SLC39A12, SLC39A13, SLC39A14) basolateral iron transporter (SLC40A1) MgtE-like magnesium transporter (SLC41A1, SLC41A2, SLC41A3) Ammonia transporter (RHAG(SLC42A1), RHBG(SLC42A2), RHCG(SLC42A3)) Na+-independent, system-L like amino acid transporter (SLC43A1, SLC43A2, SLC43A3) Choline-like transporter (SLC44A1, SLC44A2, SLC44A3, SLC44A4, SLC44A5) Putative sugar transporter (SLC45A1, SLC45A2, SLC45A3, SLC45A4) Folate transporter (SLC46A1, SLC46A2, SLC46A3) multidrug and toxin extrusion (SLC47A1, SLC47A2) Heme transporter family (SLC48A1) Heme transporter (FLVCR1(SLC49A1), FLVCR2(SLC49A2), SLC49A3, SLC49A4) Sugar efflux transporters of the SWEET family (SLC50A1) Transporters of steroid-derived molecules (SLC51A, SLC51B) Riboflavin transporter family RFVT/SLC52 (SLC52A1, SLC52A2, SLC52A3) Phosphate carriers (XPR1(SLC53A1)) Mitochondrial pyruvate carriers (MPC1(SLC54A1), MPC2(SLC54A2), MPC1L(SLC54A3)) Mitochondrial cation/proton exchangers (LETM1(SLC55A1), LETM2(SLC55A2), LETMD1(SLC55A3)) Sideroflexins (SFXN1(SLC56A1), SFXN2(SLC56A2), SFXN3(SLC56A3), SFXN4(SLC56A4), SFXN5(SLC56A5)) NiPA-like magnesium transporter family (NIPA1(SLC57A1), NIPA2(SLC57A2), NIPAL1(SLC57A3), NIPAL2(SLC57A4), NIPAL3(SLC57A5), NIPAL4(SLC57A6)) MagT-like magnesium transporter family (MAGT1(SLC58A1), TUSC3(SLC58A2)) Sodium-dependent lysophosphatidylcholine symporter family (MFSD2A(SLC59A1), MFSD2B(SLC59A2)) Glucose transporters (MFSD4A(SLC60A1), MFSD4B(SLC60A2)) Molybdate transporter family (MFSD5(SLC61A1)) Pyrophosphate transporters (ANKH(SLC62A1)) Sphingosine-phosphate transporters (SPNS1(SLC63A1), SPNS2(SLC63A2), SPNS3(SLC63A3)) Golgi Ca2+/H+ exchangers (TMEM165(SLC64A1)) NPC-type cholesterol transporters (NPC1(SLC65A1), NPC1L1(SLC65A2)) Cationic amino acid exporters (SLC66A1, SLC66A2, SLC66A3, CTNS(SLC66A4), MPDU1(SLC66A5))
p is the pressure ρ is the density and ρ(p) indicates that it is a function of pressure v is the flow speed Ψ is the potential associated with the conservative force field, often the gravitational potential In engineering situations, elevations are generally small compared to the size of the Earth, and the time scales of fluid flow are small enough to consider the equation of state as adiabatic. In this case, the above equation for an ideal gas becomes:
=== Longevity === Giant tortoises are among the longest-lived vertebrate animals (over 100 years by some estimates) and have been used as a model for studying longevity. DNA analysis of the genomes of Lonesome George, the iconic last member of Chelonoidis abingdonii, and the Aldabra giant tortoise Aldabrachelys gigantea led to the detection of lineage-specific variants affecting DNA repair genes that might contribute to our understanding of increased lifespan.
Sources: en.wikipedia.org
RP-HPLC purity is the relative area of the main peptide peak compared with the total integrated peak area. It reflects ultraviolet-absorbing species under one set of separation conditions. It does not identify every impurity or measure biological activity.
Chromatographic conditions such as column chemistry, gradient slope, mobile-phase additives, and detection wavelength affect peak resolution. Sample preparation and integration rules also influence area percent values. Without a shared reference standard and validated method, direct comparisons remain uncertain.
Purity describes the proportion of the main peak among detected components. Peptide content measures the amount of the target peptide in a sample after accounting for counterions, water, and residual salts. A sample can have high chromatographic purity but lower net peptide content.
Purity percentages vary because each laboratory uses its own column, mobile phase, gradient, detection wavelength, and integration settings. A 95% value from one method may not equal 95% from another method. Comparative assessment requires the same validated procedure or an orthogonal cross-check.